Axsome Therapeutics Q3 2026 net loss narrows 73% year over year to $12.88 million

Bitget2026/11/02 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Axsome Therapeutics’ third-quarter 2026 net loss narrowed 73% year over year to $12.88 million.
Total net product revenue climbed 52% year over year to $259.7 million.
AUVELITY prescriptions rose 40% year over year to approximately 302,000, with new patient starts increasing 44% to an undisclosed total.
The SUMMIT Phase 3 smoking-cessation trial began in August 2026; topline results are expected in the second half of 2027.
Management expects current cash to fund anticipated operations into cash flow positivity under its current operating plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020700PRIMZONEFULLFEED9867785) on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Axsome Therapeutics Q3 2026 net loss narrows 73% year over year to $12.88 million

You may also like

Crypto prices